Effects of simvastatin on liver and plasma levels of cholesterol, dolichol and ubiquinol in hypercholesterolemic rats

Ital J Biochem. 1995 Jan-Feb;44(1):1-9.

Abstract

Increased levels of blood cholesterol are considered as a major factor in the development of atherosclerosis. Simvastatin, a drug which blocks hydroxymethylglutaryl coenzyme A reductase (HMGCoAR), reduces plasma cholesterol and increases HDL-cholesterol in rats fed a hypercholesterolemic diet. Moreover, simvastatin produces a significant decrease of ubiquinol and dolichol in plasma and in liver.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cholesterol / blood
  • Cholesterol / metabolism*
  • Cholesterol, Dietary / administration & dosage
  • Cholesterol, HDL / blood
  • Dolichols / blood
  • Dolichols / metabolism*
  • Hypercholesterolemia / etiology
  • Hypercholesterolemia / metabolism*
  • Liver / drug effects
  • Liver / metabolism*
  • Lovastatin / analogs & derivatives*
  • Lovastatin / pharmacology
  • Malondialdehyde / blood
  • Rats
  • Rats, Sprague-Dawley
  • Simvastatin
  • Triglycerides / blood
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / blood
  • Ubiquinone / metabolism

Substances

  • Cholesterol, Dietary
  • Cholesterol, HDL
  • Dolichols
  • Triglycerides
  • Ubiquinone
  • Malondialdehyde
  • Cholesterol
  • Lovastatin
  • Simvastatin
  • ubiquinol